Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370623 | 0.82 | MAPK1 (0.39) | ALDH1A1CYP2C9L3MBTL1LMNAMAPT | |
| SCHEMBL5368047 | 0.81 | CYP2C9 (0.36) | ALDH1A1CYP2C9L3MBTL1LMNAMAPT | |
| SCHEMBL5366904 | 0.78 | CYP2C9 (0.36) | ALDH1A1CYP2C9MAPTKMT2A | |
| SCHEMBL5367178 | 0.78 | CYP2C9 (0.36) | ALDH1A1CYP2C9MAPTKMT2A | |
| SCHEMBL5364331 | 0.75 | BRS3 (0.40) | ALDH1A1CYP2C9L3MBTL1LMNAMAPT | |
| SCHEMBL5762846 | 0.73 | CYP2C9 (0.35) | ALDH1A1CYP2C9MAPTKMT2A | |
| SCHEMBL5763887 | 0.72 | CYP2C9 (0.36) | ALDH1A1CYP2C9MAPTKMT2A | |
| SCHEMBL5760319 | 0.71 | CYP2C9 (0.38) | ALDH1A1CYP2C9LMNAMAPTKMT2A | |
| SCHEMBL5368056 | 0.71 | CYP2C9 (0.35) | ALDH1A1CYP2C9L3MBTL1LMNAMAPT | |
| SCHEMBL5368039 | 0.71 | CYP2C9 (0.33) | ALDH1A1CYP2C9L3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | ALDH1A1 1650/4885CYP2C9 59/4885L3MBTL1 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.